Le jeudi 2 octobre, Madame Chloé DENIS, titulaire d'un Master en médecine et d'un Certificat de formation à la recherche en sciences médicales, présentera l'examen en vue de l'obtention du grade de Doctorat en sciences médicales, sous la direction de Madame Nadia WITHOFS et de Monsieur Brieuc SAUTOIS.

Cette épreuve consistera en la défense publique d'une thèse intitulée : "Evaluation of [68Ga]Ga-PSMA-11 PET/CT in the early therapeutic assessment of metastatic castration-resistant prostate cancer patients treated by first-line novel hormonal agents". 

Le jury sera composé de :

Vincent BOURS (Président), Claire JOSSE (Secrétaire), Désirée DEANDREIS (Univ. Paris Sarclay), Philippe DELVENNE, Roland HUSTINX, Guy JERUSALEM, François LALLEMAND,  Brieuc SAUTOIS, Emmanuel SERONT (UCLouvain), David WALTREGNY, Nadia WITHOFS.

Résumé de la thèse

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous and lethal disease. For these patients, therapy sequencing remains challenging, and selecting the most appropriate first line of treatment is essential, as less than half of the patients will receive two or more treatments. Improving patient selection and early identification of refractory patients to therapy is therefore key to extending survival in this population.

In the current era of prostate-specific membrane antigen (PSMA) PET/CT imaging, emerging data on its prognostic value and its use in monitoring systemic therapy response in mCRPC patients seem promising compared to conventional imaging (CI). By enabling a more accurate identification of progressive disease, molecular imagery could improve treatment tailoring for mCRPC patients. However, as most data are retrospective and based on small cohorts, its use is not yet recommended in clinical practice, where CI remains the gold standard.

The main aim of this work was to evaluate the use of [68Ga]Ga-PSMA-11 PET/CT in the early therapeutic assessment of mCRPC patients, where data is lacking, to identify potential prognostic and predictive biomarkers of response to therapy.